ASH 2019 Interview - Prof Peter Hillmen - Challenges in the CLL/SLL treatment landscape

Prof Peter Hillmen, University of Leeds, from Leeds in the UK discusses some of the chronic lymphocytic leukamia (CLL) updates from the ASH meeting 2019. Thank you to Leukaemia Care for sharing the interview with Lymphoma Australia.

Prof Hillmen is a leading international expert in the area of CLL and has chaired the CLL trials sub-group of the National Cancer Research Institute (NCRI) in the UK since 2002 and is a member of the Haematological Oncology Clinical Study Group of the NCRI.

Prof Hillman discusses some of the challenges of the rapidly changing treatment landscape for CLL/SLL with many novel therapies on the market. The challenges faced by patients receiving some of these novel therapies for CLL/SLL in the UK and around the world. These medicines have a high financial cost for health systems and so clinical trials are important to show that they work well that helps with including these treatments.

Abstracts from ASH 2019 Prof Hillman co-authored:

Hillmen, P. 
355 - Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-
Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
356 - Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and
Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses
of the Murano Trial
499 - Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia
(CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia
(BGB-3111-304) Trial
1740 - Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic
Lymphocytic Leukaemia
1768 - UK CLL Forum 5 Year Update on 315 Relapsed Refractory CLL Patients Treated with Ibrutinib in 66
UK and Ireland Centres
2503 - Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic
Anemia
2821 - 40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the
MCL Biobank Observational Study
3039 -  Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia:
42-Month Follow-up of a Phase 2 Study
3054 - Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma
3989 - R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK
Inhibitor Therapy
4307 - Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory
(R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)